Isosorbide Mononitrate tablet(IR/ER) bulk supplier for pharma manufacturers

Isosorbide Mononitrate Tablet(Ir/Er) Suppliers & Bulk Manufacturers

Available Forms: Tablet(IR & ER)

Available Strengths: ER: 30 mg, 60 mg, 120 mg; IR: 20 mg, 30 mg, 40 mg

Reference Brands: Imdur (US & EU)

Category: Heart Disorder

Isosorbide Mononitrate tablet(IR/ER) is available in Tablet(IR & ER) and strengths such as ER: 30 mg, 60 mg, 120 mg; IR: 20 mg, 30 mg, 40 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Isosorbide Mononitrate tablet(IR/ER) is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Technical Specifications & Supply Details
Lead Time 7 to 60 days (depending on batch size & schedule)
MOQ As per manufacturer’s batch size
COA Available with every batch
Regulatory Dossier / DMF Available upon request
Export Documentation FSC, COA, Manufacturing License, Product Permission
Standards IP, BP, USP
Certifications WHO-GMP, EU-GMP, USFDA (as applicable)

Isosorbide Mononitrate tablet(IR/ER) can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

📘 Sourcing Guide
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing

Product Description:

Isosorbide mononitrate tablets, marketed as Imdur, are approved in the US by the FDA and in the EU via EMA for chronic stable angina. Regulatory approval requires a detailed dossier including clinical efficacy, safety profiles, manufacturing standards, and pharmacovigilance plans. The FDA reviews clinical trial data and quality information for timely approval, while the EMA ensures compliance with regional safety and manufacturing standards. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Ensuring compliance supports timely approval, safe use, and worldwide availability, helping patients manage angina effectively and improve their quality of life globally.

Frequently Asked Questions

Yes, Isosorbide Mononitrate tablet(IR/ER) is available with DMF and other regulatory documents such as COA and MSDS. These can be provided upon request for qualified buyers.

Absolutely. Sample requests are accepted for formulation trials and quality checks. Please submit an enquiry to initiate the process.

Our manufacturing partners are GMP-certified and comply with ISO and WHO standards, ensuring global quality benchmarks.

Lead times vary based on quantity and destination, but most orders are fulfilled within 1–3 weeks. Express shipping options are available.

Yes, Isosorbide Mononitrate tablet(IR/ER) is exported to over 30 countries across Asia, Africa, Europe, and Latin America. We support documentation for customs and regulatory clearance.

Related Products

Aliskiren Tablets

Strength:
150 mg, 300 mg

Form: Tablets

Reference Brands: Tekturna(US & EU)

View Details
Atenolol Tablets

Strength:
25 mg, 50 mg, 100 mg

Form: Tablets

Reference Brands: Tenormin(US)

View Details
Metoprolol Tartrate Tablet

Strength:
IR: 25 mg, 50 mg, 100 mg; ER: 25 mg, 50 mg, 100 mg, 200 mg

Form: Tablets(IR & ER)

Reference Brands: US: Lopressor(IR); Toprol-XL(ER)

View Details
Nifedipine Tablets(Ir/Er)

Strength:
10 mg, 20 mg, 30 mg, 60 mg, 90 mg (IR and ER forms)

Form: Tablet(IR & ER)

Reference Brands: Procardia(US);

View Details
Enquire Now

Quick Response Guaranteed | Verified Suppliers

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.